Literature DB >> 3625232

Experimental autoimmune inflammatory myopathy.

M N Hart, D S Linthicum, M M Waldschmidt, S K Tassell, R L Schelper, R A Robinson.   

Abstract

We report an experimental model of autoimmune inflammatory myopathy. Splenic cells from two inbred murine strains (BALB/c and SJL/J) are activated (immunized) in vitro by co-culture with their respective syngeneic skeletal muscle myotubes. Subsequent injection of the activated splenocytes with or without B. pertussis into the respective syngeneic hosts results in inflammatory myopathy in the SJL/J mice but never in the BALB/c mice. The muscle inflammation is very similar in appearance to human autoimmune inflammatory myopathies. The myositis is not effector cell-skeletal muscle specific because splenocytes activated by co-culture with smooth muscle will also elicit skeletal muscle lesions. Both strains of skeletal muscle appear to express class II (Ia) antigens and the splenocytes from both strains appear to be equally activated. Thus we postulate that the difference in the expression of myositis between the two strains is in the effector phase of the disease. Since SJL/J mice have vasoactive amine sensitive vascular systems and BALB/c do not, it is likely that activated splenocytes emigrate from muscle microvessels in the SJL/J strain whereas they cannot do so in the BALB/c strain. The most significant contribution of this model may be in its potential for addressing a sine qua non of cellular autoimmune disease, i.e. lymphocyte migration from the vascular compartment into the target tissue. Finally, the data support a cellular more than a humoral pathogenesis in this model.

Entities:  

Mesh:

Year:  1987        PMID: 3625232     DOI: 10.1097/00005072-198709000-00001

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  5 in total

Review 1.  Membrane repair and immunological danger.

Authors:  Norma W Andrews
Journal:  EMBO Rep       Date:  2005-09       Impact factor: 8.807

2.  Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin.

Authors:  Mario Orozco-Morales; Francisco-Javier Sánchez-García; Patricia Guevara-Salazar; Oscar Arrieta; Norma Y Hernández-Pedro; Aurora Sánchez-García; Rodolfo Perez-Madrigal; Edgar Rangel-López; Benjamín Pineda; Julio Sotelo
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-27       Impact factor: 4.553

3.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

4.  Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice.

Authors:  Christine A Kostek; Janice A Dominov; Jeffrey Boone Miller
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

5.  Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction: immunohistochemical analysis and transfer.

Authors:  S Matsubara; T Shima; M Takamori
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.